WO2019235732A1 - Nouveau procédé de production de modèle de xénogreffe de glioblastome - Google Patents

Nouveau procédé de production de modèle de xénogreffe de glioblastome Download PDF

Info

Publication number
WO2019235732A1
WO2019235732A1 PCT/KR2019/004574 KR2019004574W WO2019235732A1 WO 2019235732 A1 WO2019235732 A1 WO 2019235732A1 KR 2019004574 W KR2019004574 W KR 2019004574W WO 2019235732 A1 WO2019235732 A1 WO 2019235732A1
Authority
WO
WIPO (PCT)
Prior art keywords
glioblastoma
cells
patient
present
tissue
Prior art date
Application number
PCT/KR2019/004574
Other languages
English (en)
Korean (ko)
Inventor
백선하
문효은
Original Assignee
서울대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교산학협력단 filed Critical 서울대학교산학협력단
Publication of WO2019235732A1 publication Critical patent/WO2019235732A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells

Definitions

  • the present invention relates to a method for constructing a novel glioblastoma xenograft model, and more particularly to a novel glioblastoma xenograft using a patient-derived culture cell that enables a rapid treatment option selection in treating glioblastoma with a short average survival.
  • a method of making a transplant model To a method of making a transplant model.
  • Glioblastoma is a tumor originating from glial cells that are abundant in brain tissue and is known to account for 12-15% of all brain tumors. Glia cells support the tissues of the central nervous system and are located between blood vessels and nerve cells to participate in the metabolism of nerve cells, and proliferate in the event of injury or inflammation to help the cells recover. The starting tumor is glioblastoma. Glioblastomas, however, are the most common and malignant cancers in the brain and have an average survival time of less than 15 months.
  • PDX Patient-derived xenograft
  • a method of producing a tumor model by directly injecting tumor tissue obtained during glioblastoma patient surgery and injecting the tissue directly into an immune compromised mouse has been attempted, but the success rate of the tumor model is very low (20-30%),
  • the problem is that it takes months, even years, before the model is built, and there are limitations in the treatment of glioblastomas with short average survival that do not allow the patient to choose fast treatment options.
  • the present inventors have made intensive efforts to develop a glioblastoma patient-derived xenograft model that can enable patients to quickly select a treatment option within a short period of time.
  • An animal model was constructed and confirmed that this established a xenograft animal model with a high success rate of about 80% within 1-2 months and completed the present invention.
  • Another object of the present invention is to provide a method for producing a glioblastoma xenograft model using patient-derived primary cultured cells.
  • the present invention provides a method for culturing glioblastoma patient-derived cells. Specifically, the present invention provides a method of primary culture of cancer cells derived from a patient of a new glioblastoma.
  • the present invention comprises the steps of (a) finely cutting the glioblastoma patient tissue and recovering the tissue after centrifugation;
  • the method of primary culture of glioblastoma patient-derived cancer cells Provided, the method of primary culture of glioblastoma patient-derived cancer cells.
  • the present invention also comprises the steps of: (i) resuspending the primary cultured cancer cells in RPMI 1640 and HEPES containing L- glutamine; And (ii) injecting the resuspended primary cultured cells into immunodeficient mice, providing a method for preparing a glioblastoma xenograft animal model using patient derived primary cultured cells.
  • the present invention has a high success rate (tumor incidence rate 80%) in the construction of xenograft models, and the patient-derived xenograft animal model of glioblastoma according to the present invention retains the characteristics of the original tumor, and within 1-2 months Formed rapidly, allowing for fast treatment option selection in patients with glioblastomas with short survival periods.
  • a relatively small number of glioblastoma cells are required for the production of glioblastoma models, which is useful because it enables simultaneous evaluation of several treatment options.
  • FIG. 2 is a graph showing the results of dramatic increase in tumor volume for each experimental group in the produced glioblastoma xenograft model.
  • FIG. 3 shows a pathological comparison of tumor tissue cells and transplanted tumor tissue cells of a patient.
  • disease animal model in the present invention refers to an animal having a form of disease very similar to that of humans.
  • the significance of disease model animals in human disease research is due to physiological or genetic similarities between humans and animals.
  • biomedical disease model animals provide research materials for various causes, pathogenesis, and diagnosis of disease, and research on disease model animals allows for genetic, immunochemical, tumor and immune protein expression characteristics associated with disease.
  • basic data can be obtained to determine prognostic factors, to understand the interactions between expression genes and expression proteins, and to determine whether they are viable through the actual efficacy and toxicity tests of new drug candidates.
  • a brain tumor especially a glioblastoma animal model, corresponds to a disease animal model to be obtained in the present invention.
  • the term "patient-derived cell xenograft” refers to cells isolated from a patient-derived cancer tissue, in particular immune cells such as an immune compromised mouse by primary culture of such cells.
  • a customized animal model for cancer patients made by xenotransplantation of a deficient animal which has the same or similar morphological environment as the cancer, the same or similar genetic environment, and reflects the genetic, physiological and environmental characteristics of the cancer patient. Condition can be provided. Therefore, treatment of anticancer drug candidates, radiation therapy (sensitizers), immunotherapy candidates, and the like with a patient-derived xenograft animal model has the same effect as the treatment with cancer cells or cancer tissue providing cancer patients. Since it can be confirmed, using the patient-derived xenograft animal model has the advantage that it can confirm whether the anticancer agent and the like can actually show the appropriate effect on the patient.
  • animal or “experimental animal” in the present invention means any mammalian animal other than human.
  • the animals include animals of all ages including embryos, fetuses, newborns and adults.
  • Animals for use in the present invention can be used, for example, from commercial sources.
  • Such animals may be laboratory or other animals, rabbits, rodents (e.g. mice, rats, hamsters, gerbils and guinea pigs), cattle, sheep, pigs, goats, horses, dogs, cats, birds (e.g. Chickens, turkeys, ducks, geese), primates (eg, chimpanzees, monkeys, rhesus monkeys).
  • the most preferred animal is a mouse.
  • treatment in the present invention means an approach for obtaining beneficial or desirable clinical results.
  • beneficial or desirable clinical outcomes include, but are not limited to, alleviation of symptoms, reduction of disease range, stabilization of disease state (ie, not worsening), delay or slowing of disease progression, disease state Improvement or temporary mitigation and alleviation (which may be partial or total), detectable or not detected.
  • Treatment refers to both therapeutic treatment and prophylactic or preventative measures. Such treatments include the treatments required for the disorders that have already occurred as well as the disorders to be prevented. By “palliating" a disease, the extent to which the disease state and / or undesirable clinical signs and / or the time course of progression is slowed or lengthened, as compared to the case without treatment.
  • the present invention relates to a novel method for culturing glioblastoma patient-derived cells, and to a primary method for culturing glioblastoma patient-derived cells.
  • the incubation in the step (b) may be carried out at 37 °C for 1 hour to 2 hours, the tissue recovered after centrifugation in the step (c), including the FBS and DNAase With the recovered tissue after incubation for 10-20 minutes in the culture medium and centrifuged again, the recovered tissue can be comminuted.
  • the culture medium includes DMEM, MEM, RPMI 1640, IMDM, stem cell culture medium.
  • the present invention provides a method for preparing a culture medium comprising the steps of: (i) resuspending the primary cultured cells in culture medium and buffer; And (ii) injecting the resuspended primary cultured cells into an animal other than a human, the method of producing a glioblastoma xenograft animal model using patient derived primary cultured cells.
  • DMEM DMEM
  • MEM IMDM medium
  • the "animal” refers to any mammalian animal other than human.
  • the animal may be characterized as an immunodeficiency animal such as an immune compromised mouse, and an "immune deficient animal” may be a gene for some components that make up the immune system to develop glioblastoma.
  • an animal artificially damaged at the level to be manipulated so that a normal immune system is not implemented.
  • the animal may be an animal in which a nervous system is formed.
  • the animal may be an immune system mouse, or an mouse that has been manipulated to be immunodeficient.
  • injecting the appropriate cell amount into the animal model is also very important in the success rate of animal model construction. Injecting too little or too much of the cell will not result in tumor formation in the short term, or the success rate of animal model construction is low.
  • the present invention may be characterized by injecting 1.75 to 2.5 ⁇ 10 6 cancer cells per animal model in particular.
  • the injected cell number is calculated based on the mouse, and in the case of animal models of other species, the injected cell number may change.
  • the step (ii) injection may be characterized in that the injection to the subcutaneous layer of animals, specifically, immunodeficiency mice, except for humans, the injection volume in the step (ii) is 80 to 120 per animal model May be ⁇ l.
  • the success rate is very low, and it takes months and years to develop an animal model, and has a short survival period.
  • the choice of treatment options for blastomas is not very helpful.
  • the tumor when produced according to the method of the present invention, the tumor is formed within 1-2 months, the production period is very short, and the tumor success rate is very high as 80%, which is actually resistant to glioblastoma patients with conventional treatment. Screening secondary treatment options in the presence of tumors can be utilized as an efficient and rapid screening system.
  • the glioblastoma PDX of the present invention reflects the characteristics of the patient from which the transplanted glioblastoma cells are derived, and thus can be used to select a treatment method suitable for the patient.
  • the candidate treatment means a variety of treatments that can be used for the selection of a customized treatment for treating glioblastoma onset in a patient of interest, and may include all conventionally known possible treatments for glioblastoma. For example, it may be chemotherapy, radiation therapy, surgical therapy, immune cell therapy, or a combination thereof.
  • the chemotherapy refers to a method for treating glioblastoma by administering to a patient a therapeutic candidate having a commonly known anticancer activity.
  • the radiation therapy is a method of treating glioblastoma by treating radiation to the patient
  • the surgical therapy is a method of treating glioblastoma by extracting the site where glioblastoma develops as a surgical operation.
  • the immunocytotherapy method is characterized by isolating immune cells exhibiting aggression against glioblastoma from peripheral blood mononuclear cells extracted from the patient's blood, fusing them with the glioblastoma cells isolated from the patient, and then administering them back to the patient in the form of an anticancer vaccine. To treat glioblastoma of the patient.
  • glioblastoma for selection of patient-specific glioblastoma treatment, further analysis of any one or more of the genetic characteristics, immunochemical characteristics and tumor or immunoprotein expression characteristics of glioblastoma of the glioblastoma patient-derived xenograft animal model The prognosis may be characterized.
  • Confirmation of the therapeutic effect confirms whether the tumor tissue of the animal model is reduced in size or metastasis is inhibited.
  • the present invention provides a method of treating a glioblastoma cell derived from a glioblastoma patient-derived cell xenograft animal model or glioblastoma cells derived therefrom; And (b) comparing the animal model or glioblastoma cells with the candidate substance-free control group after treatment with the candidate substance, wherein tumor size of the animal model is reduced or metastasis is inhibited or the glioblastoma
  • the present invention relates to a method for screening a glioblastoma therapeutic agent comprising determining a candidate as a glioblastoma therapeutic agent when proliferation of cells is inhibited or killed.
  • the size of the tumor tissue formed in the subcutaneous of the animal model can be characterized in that it is confirmed.
  • glioblastoma therapeutic agent preferably by further analyzing any one or more of the genetic characteristics, immunochemical characteristics and tumor or immunoprotein expression characteristics of glioblastoma of the glioblastoma patient-derived xenograft animal model It may be characterized by predicting.
  • the tissues were collected in HBSS solution containing Ca / Mg, and the tissues were collected into razor blades and scissors in about 1 mm 3 pieces at each corner.
  • the small cut tissues were all transferred to tubes containing HBSS solution containing Ca / Mg and recovered by centrifugation at 1000 RPM for 4 minutes.
  • the recovered tissue was transferred to a mixed solution of PIPES and HBSS in a 1: 1 volume ratio and centrifuged for 4 minutes at 1000 RPM.
  • a 2-fold PBS solution was added to 0.05% trypsin-EDTA and treated with preactivation at 37 ° C. for 10 minutes.
  • DNA hydrolase (DNase I) was added to the trypsin-PBS solution, and the PIPES solution was added at a 1: 1 volume ratio.
  • the tissues were then incubated at 37 ° C. for 1 hour 30 minutes in a mixture of the prepared trypsin-EDTA and PIPES solution (120 mM NaCl, 5 mM KCl, 25 mM glucose, 20 mM PIPES) and DNAase. , Centrifuged at 1000 RPM for 4 minutes.
  • the tissue recovered after centrifugation was incubated in DMEM medium containing FBS and DNAase (DNase I) for 15 minutes at 37 °C, and then centrifuged for 4 minutes at 1000 RPM.
  • the recovered tissue was then ground using three glass pipettes and filtered with a 40 ⁇ m nylon mesh cell strainer.
  • Glioblastoma primary culture cells were isolated in single cells and 50U / ml penicillin and 50mg / ml streptocete in Dulbecco's modified Eagle medium (DMEM) containing 10% Fetal bovine serum (FBS). The culture was started by putting the mycin in the mixed medium. When grown to more than 80% in the T-75 flask was subcultured and stored in a nitrogen tank as the cell stock of the initial passage. Passage cells were obtained after passage 3-4 times for a total of 2 weeks.
  • DMEM Dulbecco's modified Eagle medium
  • FBS Fetal bovine serum
  • Glioblastoma xenograft models were constructed using NOD.Cg-Prkdcscid Il2rgtm1Wjl / SzJ (NSG) mice from DNA Link.
  • glioblastoma xenograft models (SNPDCX-001 to SNPDCX-010) were produced. Among them, tumors were generated in 8 mouse models except SNPDCX-002 and SNPDCX-003. Was very high at 80%.
  • FIG. 2 is a graph showing the results of dramatic increase in tumor volume for each experimental group in the produced glioblastoma xenograft model.
  • the tumor tissue of the patient and the transplanted tumor tissue were compared morphologically.
  • a sheet of tumor glial cells was confirmed in the patient tissue (left), and the tumor cells were overstained with oval nuclei and eosinophils.
  • Polygonal tumor cells with constitutive cytoplasm, microvascular proliferation and frequent mitosis were identified.
  • Xenograft model tissue cells have an overall histological similarity to patient tissue cells, but are more cytoplasmic and generally smaller than patient tissue cells. Mitosis was similar, but it was confirmed that no microvascular proliferation was present in xenograft model tissue.
  • the glioblastoma xenograft model according to the present invention retain the characteristics of the tumor of the original patient.
  • the glioblastoma xenograft model according to the present invention is a standard for selecting treatment options of patients. It can be used as an animal model.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un nouveau procédé de construction d'un modèle de xénogreffe de glioblastome et, plus particulièrement, un nouveau procédé de production d'un modèle de xénogreffe de glioblastome à l'aide de cellules cultivées dérivées d'un patient, le procédé permettant la sélection d'une option de traitement rapide par rapport au traitement du glioblastome avec un temps de survie moyen court. La présente invention présente un taux de réussite élevé (taux d'incidence de tumeur: 80 %) dans la construction de modèle de xénogreffe, et un modèle animal de xénogreffe de glioblastome dérivé d'un patient, selon la présente invention, conserve les caractéristiques de la tumeur d'origine, et puisque les tumeurs se forment rapidement en 1 à 2 mois, un patient présentant un glioblastome avec un temps de survie court peut sélectionner une option de traitement rapide. De plus, étant donné qu'un nombre relativement faible de cellules de glioblastome est nécessaire pour la production d'un modèle de glioblastome, la présente invention permet une évaluation simultanée de plusieurs options de traitement, ce qui est utile.
PCT/KR2019/004574 2018-06-05 2019-04-16 Nouveau procédé de production de modèle de xénogreffe de glioblastome WO2019235732A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0064991 2018-06-05
KR1020180064991A KR102048963B1 (ko) 2018-06-05 2018-06-05 신규한 교모세포종 이종 이식 모델의 제조 방법

Publications (1)

Publication Number Publication Date
WO2019235732A1 true WO2019235732A1 (fr) 2019-12-12

Family

ID=68731307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/004574 WO2019235732A1 (fr) 2018-06-05 2019-04-16 Nouveau procédé de production de modèle de xénogreffe de glioblastome

Country Status (2)

Country Link
KR (1) KR102048963B1 (fr)
WO (1) WO2019235732A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114214281A (zh) * 2021-12-29 2022-03-22 华中科技大学同济医学院附属同济医院 人胶质母细胞瘤细胞系gwh04及其培养方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090089120A (ko) * 2008-02-18 2009-08-21 재단법인서울대학교산학협력재단 다능성 암 줄기 세포주 및 이의 제조방법
US8551777B2 (en) * 2005-05-11 2013-10-08 Corning Incorporated In vitro tumor angiogenesis model
KR20130143532A (ko) * 2012-06-21 2013-12-31 사회복지법인 삼성생명공익재단 환자 맞춤형 교모세포종 동물 모델의 제조방법 및 이의 용도
KR20140133399A (ko) * 2013-05-07 2014-11-19 재단법인 아산사회복지재단 환자유래 일차배양 암세포의 배양방법 및 일차배양 암세포를 이용하여 제작된 암 환자와 동일한 이종 이식 동물모델의 구축 방법
KR20180000991A (ko) * 2016-06-24 2018-01-04 사회복지법인 삼성생명공익재단 환자특이적 환자 유래 세포의 제조방법 및 이의 이용

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551777B2 (en) * 2005-05-11 2013-10-08 Corning Incorporated In vitro tumor angiogenesis model
KR20090089120A (ko) * 2008-02-18 2009-08-21 재단법인서울대학교산학협력재단 다능성 암 줄기 세포주 및 이의 제조방법
KR20130143532A (ko) * 2012-06-21 2013-12-31 사회복지법인 삼성생명공익재단 환자 맞춤형 교모세포종 동물 모델의 제조방법 및 이의 용도
KR20140133399A (ko) * 2013-05-07 2014-11-19 재단법인 아산사회복지재단 환자유래 일차배양 암세포의 배양방법 및 일차배양 암세포를 이용하여 제작된 암 환자와 동일한 이종 이식 동물모델의 구축 방법
KR20180000991A (ko) * 2016-06-24 2018-01-04 사회복지법인 삼성생명공익재단 환자특이적 환자 유래 세포의 제조방법 및 이의 이용

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114214281A (zh) * 2021-12-29 2022-03-22 华中科技大学同济医学院附属同济医院 人胶质母细胞瘤细胞系gwh04及其培养方法与应用
CN114214281B (zh) * 2021-12-29 2023-11-17 华中科技大学同济医学院附属同济医院 人胶质母细胞瘤细胞系gwh04及其培养方法与应用

Also Published As

Publication number Publication date
KR102048963B1 (ko) 2019-11-26

Similar Documents

Publication Publication Date Title
Burnet Auto-immune disease: I. Modern immunological concepts
CN1812800B (zh) 用于促进和增强神经修复和再生的肌肉来源的细胞(mdc)
US20060247195A1 (en) Method of altering cell properties by administering rna
CA2226417A1 (fr) Cellules souches neuronales et leurs utilisations
WO2019151840A1 (fr) Composition pharmaceutique comprenant des mitochondries isolées pour la prévention ou le traitement de la polyarthrite rhumatoïde
Olstorn et al. Transplantation of stem cells from the adult human brain to the adult rat brain
WO2002089566A1 (fr) Modele animal de prostatisme interstitiel
Dawe et al. Morphologic changes in salivary-gland tissue of the newborn mouse exposed to parotid-tumor agent in vitro
Zhang et al. Mouse astrocytes promote microglial ramification by releasing TGF-β and forming glial fibers
Meijers et al. A model for aganglionosis in the chicken embryo
WO2019235732A1 (fr) Nouveau procédé de production de modèle de xénogreffe de glioblastome
CN117778319A (zh) 一种调节巨噬细胞极化的方法
CN106390123B (zh) miR-29及其抑制剂在制备抗器官移植排斥药物中的应用
Huang et al. Preparation of a Non-Cardiomyocyte Cell Suspension for Single-Cell RNA Sequencing from a Post-Myocardial Infarction Adult Mouse Heart
WO2019203534A1 (fr) Nouveau modèle de xénogreffe dérivé de patient d'un glioblastome et son utilisation
Praet et al. Histological characterization and quantification of cellular events following neural and fibroblast (-like) stem cell grafting in healthy and demyelinated CNS tissue
CN112430667A (zh) 一种间充质干细胞应用于帕金森病治疗效果评价方法
US6589505B1 (en) Cells that lack p19ink4d and p27kip1 activity and methods of use thereof
Li et al. Isolation of murine hepatic myeloid cells with high yield and purity using immunomagnetic beads for subset analysis
WO2024112158A1 (fr) Plateforme d'évaluation d'agent anticancéreux immunothérapeutique utilisant un système d'avatar imitant l'immunité d'un patient cancéreux
WO2021137636A1 (fr) Composition et procédé pour induire une différenciation dans des cellules myéloïdes, et leur utilisation
US20090022699A1 (en) Method Of Genotypically Modifying Cells By Administration Of RNA
WO2024186010A1 (fr) Composition pour la prévention ou le traitement de l'anosmie, comprenant un sphéroïde de cellules souches de dents de lait exfoliées humaines
WO2023143637A1 (fr) Construction et utilisation d'un micro-organe de type cerveau pratique
US20110104123A1 (en) Therapeutic protocol using stem cells in tissue and neuronal repair, maintenance, regeneration and augmentation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19815452

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19815452

Country of ref document: EP

Kind code of ref document: A1